- Home
- CYN vs NAOV Comparison
CYN vs NAOV Comparison
Compare CYN & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- NAOV
- Stock Information
- Founded
- CYN 2013
- NAOV 2003
- Country
- CYN United States
- NAOV United States
- Employees
- CYN N/A
- NAOV N/A
- Industry
- CYN EDP Services
- NAOV Industrial Specialties
- Sector
- CYN Technology
- NAOV Health Care
- Exchange
- CYN Nasdaq
- NAOV Nasdaq
- Market Cap
- CYN N/A
- NAOV 2.4M
- IPO Year
- CYN 2021
- NAOV N/A
- Fundamental
- Price
- CYN $4.36
- NAOV $4.16
- Analyst Decision
- CYN
- NAOV
- Analyst Count
- CYN 0
- NAOV 0
- Target Price
- CYN N/A
- NAOV N/A
- AVG Volume (30 Days)
- CYN 47.5K
- NAOV 1.6M
- Earning Date
- CYN 05-07-2025
- NAOV 05-19-2025
- Dividend Yield
- CYN N/A
- NAOV N/A
- EPS Growth
- CYN N/A
- NAOV N/A
- EPS
- CYN N/A
- NAOV N/A
- Revenue
- CYN $409,777.00
- NAOV $2,558,000.00
- Revenue This Year
- CYN $1,162.03
- NAOV N/A
- Revenue Next Year
- CYN $427.83
- NAOV N/A
- P/E Ratio
- CYN N/A
- NAOV N/A
- Revenue Growth
- CYN N/A
- NAOV 12.05
- 52 Week Low
- CYN $3.62
- NAOV $1.92
- 52 Week High
- CYN $2,700.00
- NAOV $16.25
- Technical
- Relative Strength Index (RSI)
- CYN 35.22
- NAOV 44.93
- Support Level
- CYN $5.05
- NAOV $2.81
- Resistance Level
- CYN $5.49
- NAOV $4.56
- Average True Range (ATR)
- CYN 0.41
- NAOV 0.66
- MACD
- CYN 0.46
- NAOV -0.19
- Stochastic Oscillator
- CYN 32.39
- NAOV 31.19
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.